The fact that dosage increases do not raise your monthly cost is a genuine advantage, especially since most tirzepatide dosing protocols involve titrating up over several months
conducted target trial emulations comparing dual GLP-1/GIP agonists to GLP-1 monotherapy in patients with type 2 diabetes, finding that dual agonists were linked to numerically lower risks of MALOs, although confidence intervals overlapped, suggesting that extended observation period and larger patient cohorts may be needed to definitively establish comparative effectiveness [61]
223 , e2431805 (2024)
This usually balances out within a week or two as your body adjusts
Common adverse events were gastrointestinal and generally mild
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
